Longitudinal "real-world" outcomes of pirfenidone in idiopathic pulmonary fibrosis in Greece

Frontiers in Medicine

Volumn 4, Issue NOV, 2017, Pages 1-1

  Tzouvelekis, Argyrios ^a,b   Karampitsakos, Theodoros ^c   Ntolios, Paschalis ^d   Tzilas, Vasilios ^a   Bouros, Evangelos ^a   Markozannes, Evangelos ^a   Malliou, Ioanna ^a   Anagnostopoulos, Aris ^a   Granitsas, Andreas ^a   Steiropoulos, Paschalis ^b   Dimakou, Katerina ^c   Chrysikos, Serafeim ^d   Koulouris, Nikolaos ^a   Bouros, Demosthenes ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Efficacy; Idiopathic pulmonary fibrosis; Pirfenidone; Safety; Treatment

Indexed keywords

EID: 85062703900     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2017.00213     Document Type: Article

References (40)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 183:788-824. doi:10.1164/rccm.2009-040GL
2. Karampitsakos T, Tzilas V, Tringidou R, Steiropoulos P, Aidinis V, Papiris SA, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther (2017) 45:1-10 doi:10.1016/j.pupt.2017.03.016
3. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev (2012) 21:355-61. doi:10.1183/09059180.00002512
4. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2006) 174:810-6. doi:10.1164/rccm.200602-163OC
5. Bouros D, Tzouvelekis A. Idiopathic pulmonary fibrosis: on the move. Lancet Respir Med (2014) 2:17-9. doi:10.1016/S2213-2600(13)70240-6
6. Spagnolo P, Sverzellati N, Rossi G, Cavazza A, Tzouvelekis A, Crestani B, et al. Idiopathic pulmonary fibrosis: an update. Ann Med (2015) 47:15-27. doi:10.3109/07853890.2014.982165
7. Spagnolo P, Tzouvelekis A, Maher TM. Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. Curr Opin Pulm Med (2015) 21:470-8. doi:10.1097/MCP.0000000000000187
8. Tzouvelekis A, Bonella F, Spagnolo P. Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2015) 11:359-70. doi:10.2147/TCRM.S69716
9. Tzouvelekis A, Tzilas V, Papiris S, Aidinis V, Bouros D. Diagnostic and prognostic challenges in idiopathic pulmonary fibrosis: a patient's "Q and A" approach. Pulm Pharmacol Ther (2017) 42:21-4. doi:10.1016/j.pupt.2016.12.002
10. Brown AW, Kaya H, Nathan SD. Lung transplantation in IIP: a review. Respirology (2016) 21:1173-84. doi:10.1111/resp.12691
11. Idiopathic Pulmonary Fibrosis Clinical Research NetworkRaghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 366:1968-77. doi:10.1056/NEJMoa1113354
12. Fletcher S, Jones MG, Spinks K, Sgalla G, Marshall BG, Limbrey R, et al. The safety of new drug treatments for idiopathic pulmonary fibrosis. Expert Opin Drug Saf (2016) 15:1483-9. doi:10.1080/14740338.2016.1218470
13. Lehtonen ST, Veijola A, Karvonen H, Lappi-Blanco E, Sormunen R, Korpela S, et al. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respir Res (2016) 17:14. doi:10.1186/s12931-016-0328-5
14. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther (1999) 291:367-73
15. Yu W, Guo F, Song X. Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models. Pharm Biol (2017) 55:450-5. doi:10.1080/13880209.2016.1247879
16. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol (2008) 590:400-8. doi:10.1016/j.ejphar.2008.06.046
17. Karampitsakos T, Woolard T, Bouros D, Tzouvelekis A. Toll-like receptors in the pathogenesis of pulmonary fibrosis. Eur J Pharmacol (2017) 808:35-43. doi:10.1016/j.ejphar.2016.06.045
18. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med (2014) 370:2083-92. doi:10.1056/NEJMoa1402582
19. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (2011) 377:1760-9. doi:10.1016/S0140-6736(11)60405-4
20. Bouros D. Pirfenidone for idiopathic pulmonary fibrosis. Lancet (2011) 377:1727-9. doi:10.1016/S0140-6736(11)60546-1
21. Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2017) 196(6):756-61. doi:10.1164/rccm.201701-0091OC
22. Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J (2016) 47:243-53. doi:10.1183/13993003.00026-2015
23. Bando M, Yamauchi H, Ogura T, Taniguchi H, Watanabe K, Azuma A, et al. Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis. Intern Med (2016) 55:443-8. doi:10.2169/internalmedicine.55.5272
24. Chaudhuri N, Duck A, Frank R, Holme J, Leonard C. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med (2014) 108:224-6. doi:10.1016/j.rmed.2013.11.005
25. Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A, et al. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: an Italian real life study. Respir Med (2015) 109:904-13. doi:10.1016/j.rmed.2015.04.010
26. Okuda R, Hagiwara E, Baba T, Kitamura H, Kato T, Ogura T. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med (2013) 107:1431-7. doi:10.1016/j.rmed.2013.06.011
27. Oltmanns U, Kahn N, Palmowski K, Trager A, Wenz H, Heussel CP, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration (2014) 88:199-207. doi:10.1159/000363064
28. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone Clinical Study Group in J. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J (2010) 35:821-9. doi:10.1183/09031936.00005209
29. Wijsenbeek MS, Grutters JC, Wuyts WA. Early experience of pirfenidone in daily clinical practice in Belgium and the Netherlands: a retrospective cohort analysis. Adv Ther (2015) 32:691-704. doi:10.1007/s12325-015-0225-1
30. Bonella F, Wessendorf TE, Costabel U. [Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis]. Dtsch Med Wochenschr (2013) 138:518-23. doi:10.1055/s-0032-1332930
31. Costabel U, Albera C, Lancaster L, Lin C, Hormel P, Hulter H, et al. An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP). Respiration (2017) 94:408-15. doi:10.1159/000479976
32. Tzouvelekis A, Tzilas V, Bouros E, Bouros D. Pirfenidone in idiopathic pulmonary fibrosis. RECAP-itulating safety into the real-world. Respiration (2017) 94:405-7. doi:10.1159/000480299
33. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 192:e3-19. doi:10.1164/rccm.201506-1063ST
34. Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology (2014) 19:740-7. doi:10.1111/resp.12297
35. Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev (2015) 24:58-64. doi:10.1183/09059180.00011514
36. Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res (2016) 3:e000105. doi:10.1136/bmjresp-2015-000105
37. Costabel U, Albera C, Bradford WZ, Hormel P, King TE Jr, Noble PW, et al. Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis (2014) 31:198-205
38. Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis-FDA review of pirfenidone and nintedanib. N Engl J Med (2015) 372:1189-91. doi:10.1056/NEJMp1500526
39. Schmidt SL, Tayob N, Han MK, Zappala C, Kervitsky D, Murray S, et al. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest (2014) 145:579-85. doi:10.1378/chest.13-0844
40. Loeh B, Drakopanagiotakis F, Bandelli GP, von der Beck D, Tello S, Cordani E, et al. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2015) 191:110-3. doi:10.1164/rccm.201406-1106LE